EUVIMEDEUVIMED entdecken
Open Access

Antibody-Suppressor CXCR5+CD8+ T Cells Are More Potent Regulators of Humoral Alloimmunity after Kidney Transplant in Mice Compared to CD4+ Regulatory T Cells

Jing L Han iD, Jason M Zimmerer iD, Qiang Zeng iD, Sachi Chaudhari iD, Anjali Satoskar iD, Mahmoud Abdel-Rasoul iD, Hope Uwase, Christopher K Breuer iD, Ginny L Bumgardner iD

The Journal of Immunology · 01.05.2024 · 212 (9) · 1504-1518

DOI: 10.4049/jimmunol.2300289 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 22.03.2024. Verfasst von Jing L Han und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Comprehensive Transplant Center, and the College of Medicine, The Ohio State University, Columbus, OH. Hauptthemen laut MEDLINE: CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, Kidney Transplantation, T-Lymphocytes, Regulatory. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NIAID NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adoptive cell therapy (ACT), especially with CD4+ regulatory T cells (CD4+ Tregs), is an emerging therapeutic strategy to minimize immunosuppression and promote long-term allograft acceptance, although much research remains to realize its potential. In this study, we investigated the potency of novel Ab-suppressor CXCR5+CD8+ T cells (CD8+ TAb-supp) in comparison with conventional CD25highFoxp3+CD4+ Tregs for suppression of humoral alloimmunity in a murine kidney transplant (KTx) model of Ab-mediated rejection (AMR). We examined quantity of peripheral blood, splenic and graft-infiltrating CD8+ TAb-supp, and CD4+ Tregs in KTx recipients and found that high alloantibody-producing CCR5 knockout KTx recipients have significantly fewer post-transplant peripheral blood and splenic CD8+ TAb-supp, as well as fewer splenic and graft-infiltrating CD4+ Tregs compared with wild-type KTx recipients. ACT with alloprimed CXCR5+CD8+ T cells reduced alloantibody titer, splenic alloprimed germinal center (GC) B cell quantity, and improved AMR histology in CCR5 knockout KTx recipients. ACT with alloprimed CD4+ Treg cells improved AMR histology without significantly inhibiting alloantibody production or the quantity of splenic alloprimed GC B cells. Studies with TCR transgenic mice confirmed Ag specificity of CD8+ TAb-supp–mediated effector function. In wild-type recipients, CD8 depletion significantly increased alloantibody titer, GC B cells, and severity of AMR pathology compared with isotype-treated controls. Anti-CD25 mAb treatment also resulted in increased but less pronounced effect on alloantibody titer, quantity of GC B cells, and AMR pathology than CD8 depletion. To our knowledge, this is the first report that CD8+ TAb-supp cells are more potent regulators of humoral alloimmunity than CD4+ Treg cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD4-Positive T-LymphocytesCD8-Positive T-LymphocytesKidney TransplantationT-Lymphocytes, RegulatoryAnimalsMiceGraft RejectionIsoantibodiesMice, Inbred C57BLMice, KnockoutMice, TransgenicReceptors, CXCR5Immunity, Humoral

Substanzen

IsoantibodiesReceptors, CXCR5CXCR5 protein, mouse

Autor:innen und Institutionen

  • Department of Surgery, Comprehensive Transplant Center, and the College of Medicine, The Ohio State University, Columbus, OH.
  • Biomedical Sciences Graduate Program, The Ohio State University College of Medicine, Columbus, OH.
  • Center for Regenerative Medicine, The Research Institute at Nationwide Children's Hospital, Columbus, OH.
  • Department of Pathology, The Ohio State University, Columbus, OH.
  • Center for Biostatistics, The Ohio State University, Columbus, OH.

ORCID-Profile: Jing L Han, Jason M Zimmerer, Qiang Zeng, Sachi Chaudhari, Anjali Satoskar, Mahmoud Abdel-Rasoul, Christopher K Breuer, Ginny L Bumgardner

Förderung

  • NCATS NIH HHS
  • NIAID NIH HHS
  • NCI NIH HHS
  • HHS | NIH | National Institute of Allergy and Infectious Diseases
  • HHS | NIH | National Cancer Institute
  • HHS | NIH | National Center for Advancing Translational Sciences

Zitieren

APA

Han, J. L., Zimmerer, J. M., Zeng, Q., Chaudhari, S., Satoskar, A., Abdel-Rasoul, M., Uwase, H., Breuer, C. K., & Bumgardner, G. L. (2024). Antibody-Suppressor CXCR5+CD8+ T Cells Are More Potent Regulators of Humoral Alloimmunity after Kidney Transplant in Mice Compared to CD4+ Regulatory T Cells. The Journal of Immunology, 212(9), 1504-1518. https://doi.org/10.4049/jimmunol.2300289

Vancouver

Han JL, Zimmerer JM, Zeng Q, Chaudhari S, Satoskar A, Abdel-Rasoul M, et al. Antibody-Suppressor CXCR5+CD8+ T Cells Are More Potent Regulators of Humoral Alloimmunity after Kidney Transplant in Mice Compared to CD4+ Regulatory T Cells. The Journal of Immunology. 2024;212(9):1504-1518. doi:10.4049/jimmunol.2300289

BibTeX
@article{Han2024,
  author = {Han, Jing L and Zimmerer, Jason M and Zeng, Qiang and Chaudhari, Sachi and Satoskar, Anjali and Abdel-Rasoul, Mahmoud and Uwase, Hope and Breuer, Christopher K and Bumgardner, Ginny L},
  title = {Antibody-Suppressor CXCR5+CD8+ T Cells Are More Potent Regulators of Humoral Alloimmunity after Kidney Transplant in Mice Compared to CD4+ Regulatory T Cells},
  journal = {The Journal of Immunology},
  year = {2024},
  volume = {212},
  number = {9},
  pages = {1504--1518},
  doi = {10.4049/jimmunol.2300289}
}
Kostenlos starten →